Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis

Allergan's second quarter exceeded expectations and full-year guidance was raised slightly, but while the aesthetics business grew, ophthalmology with a 9.4% Restasis decline was a notable outlier.